Clinical trials: Liver Carcinoma
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling…
- Trial name
- NCT07430202
- Testing
- DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that…
- Conditions
- Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma
- Trial name
- NCT06620302
- Testing
- Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan
- Where
- 21 sites in United States
- Volunteers
- 81 people
- Sponsor
- Children's Oncology Group
Hepatocellular Carcinoma
Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
In India, majority of our patients have advanced hepatocellular carcinoma (HCC) at presentation and hence are unsuitable for the available curative treatment options. In such patients the treatment options are mainly palliative.
- Trial name
- NCT02240771
- Testing
- Transarterial chemotherapy, Oral chemotherapy
- Where
- India
- Volunteers
- 124 people
- Sponsor
- All India Institute of Medical Sciences
Liver Tumor
Pediatric Hepatic Tumors
Centralized biological collection of multicentric origin, retrospective and prospective of biological samples (tissues and fluids) taken within the framework of the diagnostic and therapeutic management of children and…
- Trial name
- HEPATOBIO (NCT04274868)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Carcinoma, Hepatocellular
Testing of ADI-PEG in Hepatocellular Carcinoma
Amino acid deprivation therapy is an effective means for the treatment of some forms of cancer. Recently it has been found that human hepatocellular carcinomas (HCC) cell lines appear to require arginine for growth.
- Trial name
- NCT00056992
- Testing
- ADI-PEG 20
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- FDA Office of Orphan Products Development
Hepatocellular Carcinoma (HCC)
Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
This retrospective observational study aims to evaluate whether artificial intelligence (AI) models can predict aggressive recurrence in patients who underwent liver resection for early-stage hepatocellular carcinoma (HCC).
- Trial name
- NCT07030842
- Testing
- liver resection
- Where
- China
- Volunteers
- 579 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma, Liver Cancer
First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
MNA-3521-011 study is a multi-centre, open-label, first-in-human, phase 1a/b clinical study dose/dose frequency escalation followed by a cohort expansion part.
- Trial name
- OUTREACH (NCT02716012)
- Testing
- MTL-CEBPA, Sorafenib 200mg
- Where
- 11 sites in Singapore, Taiwan and 1 more
- Volunteers
- 75 people
- Sponsor
- Mina Alpha Limited
Hepatocellular Carcinoma
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.
- Trial name
- TACE-3 (NCT04268888)
- Testing
- Nivolumab and TACE/TAE, TACE/TAE
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 522 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Hepatocellular Carcinoma
VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway
The investigators study the VEGF signaling in HCC cell lines and its mechanism in HCC growth, proliferation and apoptosis.
- Trial name
- HCC (NCT01892072)
- Testing
- surgical treatment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
This surveillance's objectives are: 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Factors considered to have effect to safety and effectiveness
- Trial name
- NCT02269995
- Testing
- E7040
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Eisai Co., Ltd.
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Unresectable Hepatocellular Carcinoma
"cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma
This study is a single-arm, single-center, non-randomized, open-label study. A total of 37 patients with locally advanced or metastatic HCC who have not received systemic therapy, are not suitable for radical surgical resection…
- Trial name
- NCT06590844
- Testing
- Injectable coenzyme I
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these.
- Trial name
- NCT00911196
- Testing
- Retrospective analysis of already archived samples
- Where
- 3 sites in Taiwan, Thailand
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Hepatitis B, Human Papilloma Virus
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age.
- Conditions
- Hepatitis B, Human Papilloma Virus, Mental Health Issue, Cancer Liver
- Trial name
- NCT06786429
- Testing
- Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy
- Volunteers
- 2,140 people, healthy volunteers welcome
- Sponsor
- Eunice Dube
HepatoCellular Carcinoma
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis
Hepatocellular carcinoma (HCC) is one of ten leading cancer types worldwide and also in Asia, but the five-year relative survival rate is relatively quite low1-3.
- Trial name
- RHCC (NCT02309788)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Brain Tumor, Central Nervous System Tumor
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing…
- Conditions
- Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00716976
- Testing
- sodium thiosulfate, examination
- Where
- 76 sites in United States, Australia and 1 more
- Volunteers
- 131 people
- Sponsor
- Children's Oncology Group
Hepatocellular Carcinoma
Imjudo & Imfinzi PMS
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated…
- Trial name
- NCT06544629
- Where
- 6 sites in South Korea
- Volunteers
- 246 people
- Sponsor
- AstraZeneca
Liver Cancer
A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections
The purpose of this study is to draw blood from vessels near the liver in patients undergoing liver surgery. This will be performed in both patients with cancer in order to learn more about circulating tumor cells, proteins and…
- Trial name
- NCT01749332
- Testing
- Perihepatic Phlebotomy
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer Stage IV, Lung Cancer, Non-small Cell
Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Immune-checkpoint inhibitors have recently become available as a new therapy for a variety of cancers. This drugs function by boosting the anti-cancer immune response, but unfortunately, may cause off-target, non-specific immune…
- Conditions
- Lung Cancer Stage IV, Lung Cancer, Non-small Cell, Hepatitis
- Trial name
- NCT04595734
- Testing
- No intervention due to observational methods of study
- Where
- 3 sites in Australia
- Volunteers
- 500 people
- Sponsor
- Western Sydney Local Health District